Monoclonal Gammopathy of Undetermined SignificanceiStopMMNCT03327597
Iceland Screens, Treats or Prevents Multiple Myeloma
A study testing Clinical follow-up 1, Mental Health and Quality of Life questionnaire and Standard follow-up or treatment. in people with Monoclonal Gammopathy of Undetermined Significance, run by University of Iceland at 1 site in Iceland.
Trial summary
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Monoclonal Gammopathy of Undetermined Significance
- What is being tested?
- Clinical follow-up 1, Mental Health and Quality of Life questionnaire and Standard follow-up or treatment.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80,761 participants
- Where
- 1 siteIceland
- Study dates
- 1 Sep 2016to 1 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Born 1975 or earlier
- With registered address in Iceland on November 1st 2016
Who cannot join
- Prior multiple myeloma
- Lymphoproliferative disease
- Amyloidosis
- M-protein >30 g/L or involved:uninvolved serum FLC ratio >100
- Individuals with prior history of MGUS will be offered to be randomized into either moderate or intensive clinical follow-up (arms 2 or 3).
Trial locations and contacts
1 site in 1 country.
About this study
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.
Read the detailed description
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis or immunofixation electrophoresis and can be diagnosed with a blood sample. Approximately four percent of individuals 50 years or older have MGUS which is associated with a 1-2% annual risk of malignant transformation but it is impossible to predict which individuals diagnosed as having MGUS will progress and receive a diagnosis of malignant disease.
To date, no evidence is available on the benefits and harms of population-based screening for MGUS and data from prospective studies that assess the optimal follow-up of MGUS are lacking.
All individuals that are registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate in the study. After signing informed consent, serum from the participants will be analysed for MGUS. The participants will not be contacted for blood sampling. Instead, an innovative approach will be used by taking advantage of the fact that most people 40 years or older do a blood test for various reasons during a three year period. The ID-list of participants in the study will be cross-linked with all major laboratories in Iceland, covering approximately 90% of all blood sampling in Iceland. When a participant has a blood test, a small amount (1 ml) of serum will be sampled and put in a separate test tube belonging to the study and used for diagnosis of MGUS.
Participants diagnosed as having MGUS will be randomized to three different arms, of which two arms will be called into a clinical study center for two separate types of follow-up. In arm one the participants will be asked to answer an electronic Mental Health and Quality of Life questionnaire annually but receive no active follow-up. In arm two and three the participants will be asked to answer the Mental Health and QoL questionnaire but also receive follow-up according to the International Myeloma Working Group (IMWG) guidelines (arm two) or intensive (arm three) clinical follow-up. Participants without MGUS will be asked to answer Mental Health and QoL questionnaire annually.
Results from two recent, population-based studies shows that early detection of MM through follow-up of MGUS is associated with fewer major complications and 13-14% better overall survival as compared to individuals presenting with MM without previous diagnosis of MGUS.
This study aims to assess the benefits and harms of population-based screening for MGUS by analyzing overall and disease specific survival, complications associated with screening and the effects screening has on mental health and quality of life. Furthermore, the aim of the study is to evaluate the optimal follow-up strategy of MGUS and the cost-effectiveness of screening for MGUS.
- Being tested
- Clinical follow-up 1, Mental Health and Quality of Life questionnaire, Standard follow-up or treatment., Clinical follow-up 2, Clinical follow-up 3
- Keywords
- MGUS, Screening, Population-based
- Medical subject headings
- Monoclonal Gammopathy of Undetermined Significance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical follow-up 1Other
Participants receive routine care outside the bounds of the trial. No further work-up.
Mental Health and Quality of Life questionnaireOther
Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
Standard follow-up or treatment.Other
Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
Clinical follow-up 2Other
Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
Clinical follow-up 3Other
Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
Clinical follow-up controlOther
Control clinical visit
| Study group | Role | What they receive |
|---|---|---|
| Abnormal Non-MGUS | Active comparator | Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease. Receives: Other: Mental Health and Quality of Life questionnaire; Other: Standard follow-up or treatment. |
| MGUS group arm 1 | Experimental | Participants diagnosed with MGUS, randomized to group 1. Receives: Other: Clinical follow-up 1; Other: Mental Health and Quality of Life questionnaire |
| MGUS group arm 2 | Experimental | Participants diagnosed with MGUS, randomized to group 2. Receives: Other: Mental Health and Quality of Life questionnaire; Other: Clinical follow-up 2 |
| MGUS group arm 3 | Experimental | Participants diagnosed with MGUS, randomized to group 3. Receives: Other: Mental Health and Quality of Life questionnaire; Other: Clinical follow-up 3 |
| Normal group | Active comparator | Participants without MGUS. Receives: Other: Mental Health and Quality of Life questionnaire |
| Controls | Active comparator | Participants without MGUS, matched to MGUS participants by age and gender. Receives: Other: Mental Health and Quality of Life questionnaire; Other: Clinical follow-up control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Number of participants alive in each study arm
Measured: 5 years from study start.
Secondary outcomes (13)
Cause specific survival
Survival among participants diagnosed with multiple myeloma, lymphoproliferative disease and amyloidosis.
Measured: 5 years from study start
Cost-effectiveness of screening for MGUS
Will be calculated in collaboration with the Department of economy at the University of Iceland and will include standard estimates as deemed appropriate.
Measured: 5 years from study start
Global satisfaction with one´s life as assessed by the Satisfaction with life (SWLS)
Satisfaction with life scale (SWLS) is administered at baseline and during follow-up to assess global satisfaction with one's life according to the respondent ́s personal values and criteria, and therefore, is free of the researchers' personal values and criteria of specific areas of life deemed as important. SWLS is a five item self-report scale used to measure global life satisfaction. The items are scored on a 7-point scale, ranging from one (strongly disagree) to seven (strongly agree). A higher score reflects a greater satisfaction with life. Scores within 0-4 indicate minimal, 5-9 mild, 10-14 indicate moderate, 15-19 moderately, and 20-27 severe depressive symptoms. An optimal clinical cut off point for a Major Depressive Disorder (MDD) diagnosis is estimated to be a score of 12 or greater.
Measured: 5 years from study start.
Happiness as assessed by the Single item measure for happiness
The happiness question is administered at baseline and during follow-up to assess happiness. A single item measure for happiness is one question measure that assesses happiness in an individual's life. Happiness is estimated by an individual's response to the question: "By taking into account all aspects of your life, how happy do you consider yourself?" that is scored on a 10-point scale ranging from one (very unhappy) to ten (very happy). Higher scores indicate more happiness.
Measured: 5 years from study start
Resilience as assessed by The Connor-Davidson resilience scale (CD-RISC)
The Connor-Davidson resilience scale (CD-RISC) is administered once during the study period to assess and control for resilience. The CD-RISC is a 10-item self-report measure (i.e., the short form of the questionnaire) assessing resilience in the past month. Each item is assessed on a five-point scale ranging from zero to four. Scores on each item are summed, and therefore, the total scores range from zero to 40. Higher scores indicate more resilience.
Measured: 5 years from study start
Social support as assessed by the Multidimensional scale of perceived social support (MSPSS)
Multidimensional scale of perceived social support (MSPSS) is administered once during the study period to assess and control for social support. The MSPSS is a 12-item self-report questionnaire addressing relationships with family, friends, and significant other in the areas of social popularity, respect, and areas directly related to social support. Each item is assessed on a six-point scale ranging from one (Very strongly disagree) to seven (Very strongly agree). Score on each item is summed and averaged to both calculate the total scores and scale scores. Higher scores indicate more social support. Mean scores ranging from 1 to 2.9 can be considered low support, a score of 3 to 5 can be considered moderate support, and a score from 5.1 to 7 can be considered high support.
Measured: 5 years from study start
Adverse childhood experiences as assessed by the Adverse childhood experiences international questionnaire (ACE-IQ)
Adverse childhood experiences international questionnaire (ACE-IQ) is administered once during the study period to assess and control for adverse events in childhood. The ACE-IQ is 43-item self-report measure assessing adverse childhood experiences. Questions cover family dysfunction, physical, sexual and emotional abuse and neglect by parents or caregivers, peer violence, witnessing community violence, and exposure to collective violence. Some items are yes or no questions, while other items are assessed on a five-point scale ranging from one (Always) to five (Never) or a four-point scale ranging from one (Many times) to four (Never).
Measured: 5 years from study start
Depressive symptoms as assessed by the Patient health questionnaire (PHQ-9)
Patient health questionnaire (PHQ-9) is administered at baseline and during follow-up to assess depressive symptoms. The PHQ-9 is a nine item self-report questionnaire that measures frequency of depressive symptoms in the past two weeks. Each item is scored on a 4-point scale ranging from zero (none at all) to three (nearly every day). Therefore, overall scores range from zero to 27, with a higher score indicating more severe depressive symptoms. Scores between 0-4 indicate minimal depressive symptoms, 5-9 indicate mild depressive symptoms, 10-14 indicate moderate depressive symptoms, 15-19 indicate moderately severe depressive symptoms, and 20-27 indicate severe depressive. In addition, an optimal clinical cut off point for a MDD diagnosis is estimated to be a score of 12 or greater.
Measured: 5 years from study start
Anxiety symptoms as assessed by the Generalized anxiety disorder (GAD-7)
Generalized anxiety disorder (GAD-7) is administered at baseline and during follow-up to assess anxiety symptoms. The GAD-7 is a self-report measure that assesses frequency of anxiety symptoms in the past two weeks, which in part correspond to the diagnostic criteria of generalized anxiety disorder in the DSM-IV. The questionnaire consists of seven items that assess how often in the past two weeks respondents experienced various symptoms of anxiety (e.g., feeling nervous, anxious or on edge). Each item is assessed on a 4-point scale that ranges from zero (not at all) to three (nearly every day). Total scores therefore range from zero to 21, with a higher score indicating more severe anxiety symptoms. Scores between 0-4 indicate minimal anxiety symptoms, 5-9 mild anxiety symptoms, 10-14 moderate anxiety symptoms, and 15-21 severe anxiety symptoms (Spitzer et al., 2006). In addition, an optimal clinical cut off point for a GAD diagnosis is estimated to be a score of 10 or greater
Measured: 5 years from study start
Worry as assessed by the Single item measure for worry
The worry question is administered at baseline and during follow-up to assess worry thoughts. The single item measure for worry is a single item measure for health-related worry. Worry is estimated by an individual's response to the question: "How much do you worry about your health?" that is scored on a 10-point scale ranging from one (very little) to ten (very much). Higher scores indicate more worry.
Measured: 5 years from study start
Stress as assessed by the Perceived stress scale (PSS-10)
Perceived stress scale (PSS-10) is administered during follow-up. The PSS-10 is a 10-item self-report measure on the degree in which life situations are appraised as stressful (i.e., unpredictable, uncontrollable, and overloading). PSS-10 is a 10-item self-report measure that assess the degree to which life situations were appraised as stressful in the past month, in particular how unpredictable, uncontrollable, and overloading individuals find their lives. Each item measures the frequency on a 5-point scale that ranges from 0 (never) to 4 (very often). The total score is calculated by reversing scores on four positively phrased items, and thereafter, summing the scores on each item. Total scores range from 0 to 40. Scores between 0-13 indicate low perceived stress, 14-26 moderate perceived stress, and 27-40 high perceived stress.
Measured: 5 years from study start
Post-traumatic stress symptoms as assessed by the Posttraumatic stress disorder checklist for DMS-5 (PCL-5) including the Life Events Checklist for DSM-5 (LEC-5)
Posttraumatic stress disorder checklist for DMS-5 (PCL-5) including the Life Events Checklist for DSM-5 (LEC-5) is administered during follow-up. The PCL-5 is a 20-item self-report measure that assesses the severity of PTSD symptoms in the past month. Each item assesses a symptom of PTSD. The items on the PCL-5 measure how much an individual has been bothered by each symptom associated with a particular stressful event on a five-point scale ranging from zero (not at all) to four (extremely). Total scores range from 0-80 and higher scores indicate more severe symptoms of PTSD. According to previous studies a score of 33 or higher indicates the presence of clinically significant PTSD symptoms. The LEC is a self-report instrument that screens for 16 lifetime traumatic events that are known to potentially result in clinically significant distress including PTSD, in addition, other stressful events not captured by the 16 items can be reported
Measured: 5 years from study start
Health as assessed by the 36-Item short form survey (SF-36)
36-Item short form survey (SF-36) is administered during follow-up. The SF-36 is a 36-item questionnaire assessing physical functioning, bodily pain, role limitations due to physical health and personal or emotional problems, general psychiatric health, social functioning, energy and fatigue, and general health perceptions. The measure also includes a single item that provides an indication of perceived change in health. Each item is assessed on a six-point scale ranging from one to six, which are recoded per a scoring key so that values range from zero to 100. Scores indicate the percentage of total possible score achieved. All items are recoded so that a high score indicates a more favorable health state. Thereafter, the average score is calculated for each scale. Items that are left blank (missing data) are not considered when calculating the scale scores.
Measured: 5 years from study start
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2017
- Study start1 Sep 2016
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Monoclonal Gammopathy of Undetermined SignificanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80,761 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Iceland
- Sponsor type
- University, hospital or other
- Collaborators
- Landspitali University Hospital, Union for International Cancer Control, Icelandic Heart Association, deCODE genetics, International Myeloma Foundation/Black Swan Research Initiative, The Binding Site, Memorial Sloan Kettering Cancer Center, European Research Council, Icelandic Research Center
- Responsible party
- Sponsor
- Investigators
- Sigurdur Y Kristinsson, Professor, Principal investigator, University of Iceland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03327597
- Sponsor's protocol ID
- UI-2017-MGUS
- Acronym
- iStopMM
- Status last verified
- Sep 2025
- First submitted
- 19 Oct 2017
- Last updated
- 30 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rognvaldsson S, Thorsteinsdottir S, Eythorsson E, Wessman ID, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson B, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Bjornsson AS, Oskarsson JT, Olafsson A, Gislason G, Sverrisdottir I, Long TE, Guethmundsdottir ER, Thordardottir AR, Jonsson A, Palsson R, Indridason OS, Hultcrantz M, Durie BGM, Harding SJ, Aspelund T, Landgren O, Love TJ, Kristinsson SY. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. J Clin Oncol. 2026 Jul 14:JCO2502771. doi: 10.1200/JCO-25-02771. Online ahead of print.
PubMed 42447419Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, Einarsson Long T, Reed ER, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Sveinsdottir SV, Sigurdsson F, Thordardottir AR, Palsson R, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Sigurdsson J, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Aspelund T, Love TJ, Kristinsson SY. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial. Ann Intern Med. 2024 Apr;177(4):449-457. doi: 10.7326/M23-2540. Epub 2024 Apr 2.
PubMed 38560901Sigurbergsdottir AY, Rognvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Sigurethardottir GA, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Thornorethardottir AR, Gislason GK, Olafsson A, Hultcrantz M, Durie BGM, Harding S, Landgren O, Love TJ, Kristinsson SY. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study. Haematologica. 2023 Dec 1;108(12):3392-3398. doi: 10.3324/haematol.2023.283191.
PubMed 37439374Thorsteinsdottir S, Gislason GK, Aspelund T, Rognvaldsson S, Oskarsson JThorn, Sigurethardottir GA, Thornorethardottir AR, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Eythornorsson E, Jonsson A, Berlanga O, Hultcrantz M, Durie BGM, Love TJ, Harding S, Landgren O, Kristinsson SY. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023 Feb;29(2):467-472. doi: 10.1038/s41591-022-02183-6. Epub 2023 Feb 6.
PubMed 36747117
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Iceland Screens, Treats or Prevents Multiple Myeloma
- ClinicalTrials.gov ID
- NCT03327597
- Acronym / sponsor ID
- iStopMM / UI-2017-MGUS
- Keywords
- MGUS, Screening, Population-based
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 80,761 participants (actual)
- Lead sponsor
- University of IcelandUniversity, hospital or other
- Collaborators
- Landspitali University Hospital, Union for International Cancer Control, Icelandic Heart Association, deCODE genetics, International Myeloma Foundation/Black Swan Research Initiative, The Binding Site, Memorial Sloan Kettering Cancer Center, European Research Council, Icelandic Research Center
- Study start
- 1 Sep 2016 (actual)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 31 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.
Detailed description
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis or immunofixation electrophoresis and can be diagnosed with a blood sample. Approximately four percent of individuals 50 years or older have MGUS which is associated with a 1-2% annual risk of malignant transformation but it is impossible to predict which individuals diagnosed as having MGUS will progress and receive a diagnosis of malignant disease.
To date, no evidence is available on the benefits and harms of population-based screening for MGUS and data from prospective studies that assess the optimal follow-up of MGUS are lacking.
All individuals that are registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate in the study. After signing informed consent, serum from the participants will be analysed for MGUS. The participants will not be contacted for blood sampling. Instead, an innovative approach will be used by taking advantage of the fact that most people 40 years or older do a blood test for various reasons during a three year period. The ID-list of participants in the study will be cross-linked with all major laboratories in Iceland, covering approximately 90% of all blood sampling in Iceland. When a participant has a blood test, a small amount (1 ml) of serum will be sampled and put in a separate test tube belonging to the study and used for diagnosis of MGUS.
Participants diagnosed as having MGUS will be randomized to three different arms, of which two arms will be called into a clinical study center for two separate types of follow-up. In arm one the participants will be asked to answer an electronic Mental Health and Quality of Life questionnaire annually but receive no active follow-up. In arm two and three the participants will be asked to answer the Mental Health and QoL questionnaire but also receive follow-up according to the International Myeloma Working Group (IMWG) guidelines (arm two) or intensive (arm three) clinical follow-up. Participants without MGUS will be asked to answer Mental Health and QoL questionnaire annually.
Results from two recent, population-based studies shows that early detection of MM through follow-up of MGUS is associated with fewer major complications and 13-14% better overall survival as compared to individuals presenting with MM without previous diagnosis of MGUS.
This study aims to assess the benefits and harms of population-based screening for MGUS by analyzing overall and disease specific survival, complications associated with screening and the effects screening has on mental health and quality of life. Furthermore, the aim of the study is to evaluate the optimal follow-up strategy of MGUS and the cost-effectiveness of screening for MGUS.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Abnormal Non-MGUS | Active comparator | Other: Mental Health and Quality of Life questionnaire, Other: Standard follow-up or treatment.Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease. |
| MGUS group arm 1 | Experimental | Other: Clinical follow-up 1, Other: Mental Health and Quality of Life questionnaireParticipants diagnosed with MGUS, randomized to group 1. |
| MGUS group arm 2 | Experimental | Other: Mental Health and Quality of Life questionnaire, Other: Clinical follow-up 2Participants diagnosed with MGUS, randomized to group 2. |
| MGUS group arm 3 | Experimental | Other: Mental Health and Quality of Life questionnaire, Other: Clinical follow-up 3Participants diagnosed with MGUS, randomized to group 3. |
| Normal group | Active comparator | Other: Mental Health and Quality of Life questionnaireParticipants without MGUS. |
| Controls | Active comparator | Other: Mental Health and Quality of Life questionnaire, Other: Clinical follow-up controlParticipants without MGUS, matched to MGUS participants by age and gender. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Born 1975 or earlier
- With registered address in Iceland on November 1st 2016
Key exclusion criteria (5 listed)
- Prior multiple myeloma
- Lymphoproliferative disease
- Amyloidosis
- M-protein >30 g/L or involved:uninvolved serum FLC ratio >100
- Individuals with prior history of MGUS will be offered to be randomized into either moderate or intensive clinical follow-up (arms 2 or 3).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical follow-up 1Participants receive routine care outside the bounds of the trial. No further work-up. | Other | MGUS group arm 1 |
| Mental Health and Quality of Life questionnaireParticipants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is) | Other | Abnormal Non-MGUS, Controls, MGUS group arm 1, MGUS group arm 2, MGUS group arm 3, Normal group |
| Standard follow-up or treatment.Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment. | Other | Abnormal Non-MGUS |
| Clinical follow-up 2Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines. | Other | MGUS group arm 2 |
| Clinical follow-up 3Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging. | Other | MGUS group arm 3 |
| Clinical follow-up controlControl clinical visit | Other | Controls |
Primary outcome
Overall survival
Time frame: 5 years from study start.
Number of participants alive in each study arm
13 secondary outcomes
Cause specific survival
Time frame: 5 years from study start
Cost-effectiveness of screening for MGUS
Time frame: 5 years from study start
Global satisfaction with one´s life as assessed by the Satisfaction with life (SWLS)
Time frame: 5 years from study start.
Happiness as assessed by the Single item measure for happiness
Time frame: 5 years from study start
Resilience as assessed by The Connor-Davidson resilience scale (CD-RISC)
Time frame: 5 years from study start
Social support as assessed by the Multidimensional scale of perceived social support (MSPSS)
Time frame: 5 years from study start
Adverse childhood experiences as assessed by the Adverse childhood experiences international questionnaire (ACE-IQ)
Time frame: 5 years from study start
Depressive symptoms as assessed by the Patient health questionnaire (PHQ-9)
Time frame: 5 years from study start
Anxiety symptoms as assessed by the Generalized anxiety disorder (GAD-7)
Time frame: 5 years from study start
Worry as assessed by the Single item measure for worry
Time frame: 5 years from study start
Stress as assessed by the Perceived stress scale (PSS-10)
Time frame: 5 years from study start
Post-traumatic stress symptoms as assessed by the Posttraumatic stress disorder checklist for DMS-5 (PCL-5) including the Life Events Checklist for DSM-5 (LEC-5)
Time frame: 5 years from study start
Health as assessed by the 36-Item short form survey (SF-36)
Time frame: 5 years from study start
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2025.
- Derived from this study: PubMed 42447419Rognvaldsson S, Thorsteinsdottir S, Eythorsson E, Wessman ID, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson B, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Bjornsson AS, Oskarsson JT, Olafsson A, Gislason G, Sverrisdottir I, Long TE, Guethmundsdottir ER, Thordardottir AR, Jonsson A, Palsson R, Indridason OS, Hultcrantz M, Durie BGM, Harding SJ, Aspelund T, Landgren O, Love TJ, Kristinsson SY. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. J Clin Oncol. 2026 Jul 14:JCO2502771. doi: 10.1200/JCO-25-02771. Online ahead of print.
- Derived from this study: PubMed 38560901Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, Einarsson Long T, Reed ER, Sigurdardottir GA, Vidarsson B, Onundarson PT, Agnarsson BA, Sigurdardottir M, Olafsson I, Thorsteinsdottir I, Sveinsdottir SV, Sigurdsson F, Thordardottir AR, Palsson R, Indridason OS, Jonsson A, Gislason GK, Olafsson A, Sigurdsson J, Steingrimsdottir H, Hultcrantz M, Durie BGM, Harding S, Landgren O, Aspelund T, Love TJ, Kristinsson SY. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial. Ann Intern Med. 2024 Apr;177(4):449-457. doi: 10.7326/M23-2540. Epub 2024 Apr 2.
- Derived from this study: PubMed 37439374Sigurbergsdottir AY, Rognvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Sigurethardottir GA, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Thornorethardottir AR, Gislason GK, Olafsson A, Hultcrantz M, Durie BGM, Harding S, Landgren O, Love TJ, Kristinsson SY. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study. Haematologica. 2023 Dec 1;108(12):3392-3398. doi: 10.3324/haematol.2023.283191.
- Derived from this study: PubMed 36747117Thorsteinsdottir S, Gislason GK, Aspelund T, Rognvaldsson S, Oskarsson JThorn, Sigurethardottir GA, Thornorethardottir AR, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Eythornorsson E, Jonsson A, Berlanga O, Hultcrantz M, Durie BGM, Love TJ, Harding S, Landgren O, Kristinsson SY. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023 Feb;29(2):467-472. doi: 10.1038/s41591-022-02183-6. Epub 2023 Feb 6.
- Individual participant dataSharing planned: No
Related trials for Monoclonal Gammopathy of Undetermined Significance
RecruitingObservational study
The Indiana Myeloma Registry
Plasma Cell Dyscrasias
RecruitingObservational study
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
RecruitingObservational study
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Recruiting
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Multiple Myeloma, Smoldering, Multiple Myeloma
Active, not recruiting
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sigurdur Y Kristinsson, Professor principal investigator
University of Iceland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinical follow-up 1, Mental Health and Quality of Life questionnaire and Standard follow-up or treatment. in people with Monoclonal Gammopathy of Undetermined Significance, run by University of Iceland at 1 site in Iceland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iceland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 5 years from study start.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03327597, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2025.